Trevi Therapeutics expands at-the-market equity facility by $50M to $62M total

Trevi Therapeutics, Inc.

Amended Sales Agreement with SVB Securities to increase max aggregate offering from $12M to $62M, adding $50M in capacity.
Shares sold in ATM offerings under Rule 415; SVB receives 3.0% commission on gross proceeds.
Company will file a prospectus supplement under existing shelf registration statement (File No. 333-239499).
No obligation to sell; either party may suspend the offering at any time.
SVB affiliate Silicon Valley Bank is lender under a separate $14M term loan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.